Companies Dominating the In Situ Hybridization Landscape
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott
- PerkinElmer, Inc.
- Leica Biosystems Nussloch GmbH
- F. Hoffman-La Roche Limited
- NeoGenomics Laboratories, Inc.
- Advanced Cell Diagnostics, Inc.
- BioView
- Agilent Technologies, Inc.
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Oxford Gene Technology IP Limited
- Bio-Techne Corporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of in situ hybridization is assessed at USD 1.99 billion.
The in situ hybridization market size was over USD 1.82 billion in 2024 and is poised to reach USD 7.76 billion by the end of 2037, witnessing around 11.8% CAGR during the forecast period i.e., between 2025-2037. The rising incidence of cancer across the globe and the growing technological advancements in In-vitro diagnostics (IVD) will drive the market growth.
North America industry is poised to account for largest revenue share 45% by 2037, impelled by increasing spending in healthcare in the region.
The major players in the market are Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, and others.
